All-cause and cardiovascular mortality associated with sulphonylurea and metformin therapy in type 2 diabetes.

The effect on all-cause mortality was beneficial for MET+SU combined therapy, but deleterious for either SU replacing MET, or MET replacing SU. There were no major outcome differences when analyzing individual SU, or specific mortality.